23 Jul, 2026
According to Straits Research, the global meningococcal vaccine market size was valued at $4 billion in 2025 and is estimated to reach $6.62 billion by 2034, growing at a CAGR of 6.8% during the forecast period 2026–2034.
The global meningococcal vaccine market is experiencing growth driven by increasing awareness programs, including public health campaigns, healthcare provider education, and community outreach, which promote vaccine acceptance and uptake. The market is also shifting toward multivalent and next-generation vaccines that protect against multiple serogroups, simplifying immunization schedules, improving compliance, and offering broader, longer-lasting protection. Advanced conjugate technologies and expanded regulatory approvals for wider age groups further support this trend. Growth is bolstered by robust research and development efforts from pharmaceutical companies, healthcare facilities, and non-profits, driving innovation and commercialization.
However, high vaccine costs, particularly for advanced formulations, limit access in low- and middle-income countries, constraining market expansion despite rising awareness. Opportunities lie in collaborations and partnerships with NGOs, healthcare providers, and public health agencies to enhance vaccine accessibility through awareness campaigns, training for healthcare workers, and cost subsidies, particularly in underserved regions. These efforts enhance coverage, foster community trust, and unlock sustainable growth potential for manufacturers across emerging and established markets.
sales@straitsresearch.com